18 | Acquisition International, Issue 9 2023 edicated to advising the likes of CEOs, CMOs, and CSOs; the FDA, NHS, EMA, Academy of Medicine, and Ministries of Health; and PE/VC investors and startup founders, Grace Lee and her team design integrated business and health information technology using artificial intelligence-enabled infrastructure design for automating medical case processing, decision-analysis, safety tracking, public health, and competitive intelligence. Grace’s multi-faceted expertise in pharmacogenomics and DNA/protein data predictions, stem cells, drug and biotech development, business design strategy, and regulatory, clinical and data science is what her clients value most to provide customised human-centric solutions that differentiate her firm’s offering from consulting competitors. Drug and Biotech Development In the early 2000s, when the healthcare industry was beginning to evolve from paper-based to electronic NDA filings, Grace and her team developed generative AI automation technology that reduced time to process millions of serious adverse event cases by over 400%. In applying natural language models to digest complex medical details for human expert evaluations, Grace has helped upwards of 150 drug and biotech companies to save hundreds of millions of dollars in cost, time, and effort to expedite safety analysis for faster drug approval and more diligent protection of patients. Competitive Analysis for C-Level Executives Between 2011 and 2014, Grace built Clinical and Safety Signal (CLASS) technology which collected and integrated unstructured information from clinical trials globally in real-time and compared clinical safety signals of competitive therapies for each drug class for regulators, drug developers, and public health experts to access information with just three clicks. This technology was featured by Google and Gartner at their conferences to demonstrate how integration of cloud data across global platforms could provide competitive intelligence and comparative analysis of safety profiles to protect patients and identify new uses for existing products. Public Health Effectiveness Between 2014 and 2020, Grace and her team designed an integrated public health, clinical care, and biomedical research platform for Qatar Supreme Council of Health. This innovative design enabled regulators, policy makers, hospital executives, doctors, researchers, and even patients and their caregivers to have integrated information on-demand from a single source of truth. By layering different technologies and simultaneously enabling the collection, standardisation, integration, and analysis of data, this design leverages concurrent use of the technology outputs to determine how it can iteratively be built. Investor Due Diligence and Founder Advisory Between 2016 and present day, Health Enovation has been advising and providing due diligence for more than 700 investors and founders of startups on strategic approaches to building health technology that integrates business process, data flow, and customer/patient needs for scalability and acceptability by users, regulators, and clinical leaders. By diagnosing risks and challenges from the human and data perspectives, Grace Lee is a serial entrepreneur who for more than 25 years has been an industry expert and leader as a senior-level executive within the health tech, biotech, pharmaceutical, and healthcare industries. Currently, as the CEO of Health Enovation, she leads a talented team of consultants and strategists who provide health technology consulting and business strategy advisory to C-level executives. Now highly deservingly recognised within the Influential Businesswoman Awards 2023 for her extraordinary contributions to the sector, we delve deeper into the work she and her team do. D Most Innovative HealthTech CEO 2023 (USA): Grace Lee May23169
RkJQdWJsaXNoZXIy MTUyMDQwMA==